Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP

Inclusion Criteria: * \- Able and willing to provide informed consent; * Pathologically proven diagnosis of prostatic adenocarcinoma; * Biochemical failure (2 consecutive PSA rises above 0.2 ng/ml) after radical prostatectomy; * No regional or distant metastases; * Eastern Cooperative Oncology Group performance status 0-1 Exclusion Criteria: * \- Previous local treatment of the prostate with radiotherapy, brachytherapy, cryosurgery, high-intensity focused ultrasound or cryotherapy; * Previous radiotherapy to the pelvis; * Previous or current symptomatic vesicourethral anastomotic stenosis post-RP (weak stream, straining to void, hesitancy and incomplete bladder emptying); * PSA level at sRT\> 2 ng/ml; * (Each single) Lesion volume within the prostatic fossa at mpMR \>5 cc; * Previous chemotherapy for malignancy in past 5 years; * Previous androgen deprivation for biochemical failure after RP; * Contraindication to short term AD (in case of Px) * Presence of nodal or distant metastasis, as confirmed by magnetic resonance (MR) or PET/CT * Pathologically positive lymph nodes (pN+) at RP; * Serious medical comorbidities or other contraindications to radiotherapy * Presence of active inflammatory bowel disease; * Presence of active connective tissue disease; * Unable or unwilling to complete quality of life questionnaires